Anti-Human IL-23 p19 Recombinant Antibody (SAA0392), PE (HV466227)

Name: Anti-Human IL-23 p19 Recombinant Antibody (SAA0392), PE
Brand: abinScience
SKU: HV466227
Price: 256 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

50T
100T

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HV466227
Reactivité des espèces	Human
Applications	ELISA, FCM
Espèce hôte	Human
Clonalité	Monoclonal
Isotype	IgG4, kappa
ID de clone	SAA0392
Conjugaison	PE
Cible	IL-23 subunit alpha, IL-23-A, IL-23p19, IL23A, Interleukin-23 subunit alpha, Interleukin-23 subunit p19, SGRF
Niveau d'endotoxines	Please contact with the lab for this information.
Pureté	>90% as determined by SDS-PAGE.
Produits associés	Human IgG4 (S228P) Recombinant Isotype Control Antibody (13R4), PE
Numéro d'accès	Q9NPF7
Forme	Liquid
Tampon de stockage	0.01M PBS, pH 7.4, 50% glycerol, 0.05% Proclin 300. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Store at 4°C for 12 months. Protect from light. Do not freeze.
Contexte	Interleukin-23 subunit alpha (IL23A) is a ~20 kDa protein. Associates with IL12B to form the pro-inflammatory cytokine IL-23 that plays different roles in innate and adaptive immunity. Released by antigen-presenting cells such as dendritic cells or macrophages, binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R to activate JAK2 and TYK2 which then phosphorylate the receptor to form a docking site leading to the phosphorylation of STAT3 and STAT4. This process leads to activation of several pathways including p38 MAPK or NF-kappa-B and promotes the production of pro-inflammatory cytokines such as interleukin-17A/IL17A. In turn, participates in the early and effective intracellular bacterial clearance. Promotes the expansion and survival of T-helper 17 cells, a CD4-positive helper T-cell subset that produces IL-17, as well as other IL-17-producing cells. IL23A is the therapeutic target of guselkumab (Tremfya). 1. Oppmann, B. et al. (2000) Immunity 13, 715-25. PMID: 11114383 2. Bloch, Y. et al. (2018) Immunity 48, 45-58.e6. PMID: 29287995 3. Sun, R. et al. (2020) Cellular and molecular gastroenterology and hepatology 10, 673-697. PMID: 32474165 4. Glassman, CR. et al. (2021) Cell 184, 983-999.e24. PMID: 33606986 5. Parham, C. et al. (2002) Journal of immunology (Baltimore, Md. : 1950) 168, 5699-708. PMID: 12023369 6. Wilson, NJ. et al. (2007) Nature immunology 8, 950-7. PMID: 17676044
Note	For flow cytometric staining, the suggested use of this reagent is 0.5 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application. For research use only.